The EU Court of Justice Advocate General Kokott proposes to uphold the fine of almost €94 million imposed on a pharmaceutical group in the context of agreements intended to delay the marketing of generic versions of its antidepressant medicinal product citalopram (Lundbeck)

Advocate General Kokott proposes that the Court of Justice should uphold the fine of almost €94 million imposed on the Lundbeck pharmaceutical group in the context of agreements intended to delay the marketing of generic versions of its antidepressant medicinal product citalopram* The Advocate General proposes dismissing the appeal brought by Lundbeck against the judgment of the General Court upholding the Commission’s decision imposing that fine By decision of 19 June 2013, [1] the Commission imposed a fine of almost €94 million on the Danish pharmaceutical group Lundbeck, which had developed an antidepressant medicinal product containing an active ingredient called ‘citalopram’. According to the Commission, in 2002, when the patents protecting that active ingredient within the European

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Court of Justice, The EU Court of Justice Advocate General Kokott proposes to uphold the fine of almost €94 million imposed on a pharmaceutical group in the context of agreements intended to delay the marketing of generic versions of its antidepressant medicinal product citalopram (Lundbeck), 4 June 2020, e-Competitions June 2020, Art. N° 95290

Visites 354

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues